NewEast Biosciences pioneered the research and development of the antibodies for GTPases and mutated Oncogene ten years ago. GTPases involve (1) signal transduction in response to activation of cell surface receptors, including transmembrane receptors such as those mediating taste, smell and vision, (2) protein biosynthesis at the ribosome, (3) regulation of cell differentiation, proliferation, division and movement, (4) translocation of proteins through membranes, (5) transport of vesicles within the cell, and vesicle-mediated secretion and uptake, through GTPase control of vesicle coat assembly. An oncogene is a gene that has the potential to cause cancer.
We offer three unique categories of antibodies, which (1) recognize only the active configuration of GTPase (not the inactive one), (2) mutated Oncogene (not mild type) and (3) have super affinity for cAMP and cGMP (no acetylation required). We have over one thousand peer reviewed articles cited our products.
$555.00
Cat.#: 11151 | ||||
Product Name: Human PD-L1 Protein | ||||
Size : 10 µg, 50 µg and 100 µg | ||||
Synonyms: PD-L1;CD274;B7-H1;PDCD1L1;PDCD1LG1 | ||||
Target: PD-L1 | ||||
UNIPROT ID: Q9NZQ7 | ||||
Description: Recombinant human PD-L1 protein with C-terminal mouse Fc and 6xHis tag | ||||
Background: This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. | ||||
Species/Host: HEK293 | ||||
Molecular Weight: The protein has a predicted molecular mass of 52.3 kDa after removal of the signal peptide. | ||||
Molecular Characterization: PD-L1(Phe19-Arg238) mFc(Pro99-Lys330) 6×His tag | ||||
Purity: The purity of the protein is greater than 95% as determined by SDS-PAGE and Coomassie blue staining. | ||||
Formulation & Reconstitution: Lyophilized from nanodisc solubilization buffer (20 mM Tris-HCl, 150 mM NaCl, pH 8.0). Normally 5% – 8% trehalose is added as protectants before lyophilization. | ||||
Storage & Shipping: Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. | ||||
|